Dr. Ethan Rubinstein
H.E. Sellers Research Chair in Infectious Diseases
Head, Section of Infectious Diseases, Department of Internal Medicine

Degrees: M.D. (U of Basel, 1968), L.LB. (Tel-Aviv, 1991)

Mailing Address: Department of Medical Microbiology 745 Bannatyne Avenue, Room 501 Winnipeg, MB R3E 0J9

Tel: (204) 977-5681 Fax: (204) 789-3926
E-mail:rubinste@cc.umanitoba.ca

Research Interests:
1) Systemic infections
2) MRSA
3) Anthrax
4) Nosocimial pneumonia
5) Endocarditis
6) Fluoroquinolones
7) Adult vaccines

Recent Publications:
  1. Zhanel GG, Calic D, Schweizer F, Zelenitsky S, Adam H, Lagacé-Wiens PR, Rubinstein E, Gin AS, Hoban DJ, Karlowsky JA. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs. 2010 May 7; 70 (7):859-86.

  2. Sharomi O, Podder CN, Gumel AB, Mahmud SM, Rubinstein E . Modelling the Transmission Dynamics and Control of the Novel 2009 Swine Influenza (H1N1) Pandemic. Bull Math Biol. 2010 Apr 9.

  3. Lagacé-Wiens PR, Rubinstein E , Gumel A. Influenza epidemiology – past, present and future. Crit Care Med. 2010 Apr; 384 (4 Suppl):e1-9. Review.

  4. Sethi S, Jones PW, Theron MS, Miravitlles M, Rubinstein E , Wedzicha JA, Wilson R; PULSE Study group. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir Res. 2010 Jan 28: 11:10.
  5. Keynan Y, Rubinstein E . Are drug clinical trials broadly applicable? The case of staphylococcal bacteraemia. Int J Antimicrob Agents. 2009; 34 Suppl 4:S35-7.

  6. Lagacé-Wiens PR, Rubinstein E , Gumel A. Influenza epidemiology-past, present, and future. Crit Care Med 2009 Dec 19. [Epub ahead of print]

      
  7. Regev-Yochay G, Raz M, Carmeli Y, Shainberg B, Navon-Venezia S, Pinco E, Leavitt A, Keller N, Rahav G, Malley R, Rubinstein E ; the Maccabi implementing Judicious Antibiotic Prescription Study Group. Parental Staphylococcus aureus Carriage is Associated with Staphylococcal Carriage in Young Children. Pediatr Infect Dis J. 2009 Nov; 28(11): 960-965
  8. Vinh DC, Rubinstein E . Linezolid: a review of safety and tolerability. J Infect. 2009 Sep; 59S1:S59-S74.
  9. Zhanel GG, Ketter N, Rubinstein E , Friedland I, Redman R. Overview of seizure-inducing potential of doripenem. Drug Saf. 2009; 32(9):709-16.
  10. Fanella S, Schantz D, Karlowsky J, Rubinstein E . Septic Arthritis Due to Roseomonas gilardii In An Immunocompetent Adolescent. J Med Microbiol. 2009 Jul 2. [Epub ahead of print].
  11. Zhanel GG, Sniezek G, Schweizer F, Zelenitsky S, Lagacé-Wiens PR, Rubinstein E , Gin AS, Hoban DJ, Karlowsky JA. Ceftaroline: A Novel Broad-Spectrum Cephalosporin with Activity against Methicillin-Resistant Staphylococcus aureus. Drugs. 2009; 69(7):809-31.
  12. Naber CK, Baddour LM, Giamarellos-Bourboulis EJ, Gould IM, Hermann M, Hoen B, Karchmer AW, Kobayashi Y, Kozlov RS, Lew D, Miró JM, Moellering RC Jr, Moreillon P, Peters G, Rubinstein E , Seifert H, Corey Gr. Clinical consensus conference: survey on Gram-positive bloodstream infections with a focus on Staphylococcus aureus. Clin Infect Dis. 2009 May 15; 48 Suppl 4:260-70.
  13. Weiss G, Reimmitz P, Hampel B, Muehlhofer E, Lippert H; AIDA Study Group. Moxifloxacin for the treatment of patients with complicated intra-abdominal infections (the AIDA Study). J Chemother. 2009 Apr; 21(2):170-80.
  14. Benito N, Miró JM, de Lazzari E, Cabell CH, del Río A, Altclas J, Commerford P, Delahaye F, Dragulescu S, Giamarellou H, Habib G, Kamarulzaman A, Kumar AS, Nacinovich FM, Suter F, Tribouilloy C, Venugopal K, Moreno A, Fowler VG Jr ; ICE-PCS (International Collaboration on Endocarditis Prospective Cohort Study) Investigators. Health care-associated native valve endocarditis: importance of non-nosocomial acquisition. Ann Intern Med. 2009 May 5;150(9):586-94
  15. Regev-Yochay G, Lipsitch M, Basset A, Rubinstein E , Dagan R, Raz M, Malley R. The Pnuemococcal Pilus Predicts the Absence of Staphylococcus aureus Co-Colonization in Pnuemococcal Carriers. Clin Infect Dis 2009 Mar 15:48:760-3.
  16. Murdoch DR, Corey GR, Hoen B, Miró JM, Fowler VG Jr, Bayer AS, Karchmer AW, Olaison L, Pappas PA, Moreillon P, Chambers ST, Chu VH, Falcó V, Holland DJ, Jones P, Klein JL, Raymond NJ, Read KM, Tripodi MF, Utili R, Wang A, Woods CW, Cabell CH; International Collaboration on Endocarditis-Prospective Cohort Study (ICE-PCS) Investigators . Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study. Arch Intern Med. 2009 Mar 9; 169(5):463-73.
  17. Keynan Y, Larios OE, Wiseman WC, Plourde M, Ouellette M, Rubinstein E . Use of oral miltefosine for cutaneous leishmaniasis in Canadian soldiers returning from Afghanistan. Can J Infect Dis Med Microbiol. 2008 Nov; 19(6):394-6.
  18. Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, Nadler J, Clotet B, Karlsson A, Wohfeiler M, Montana JB, McHale M, Sullivan J, Ridgway C, Felstead S, Dunne MW, van der Ryst E, Mayer H, MOTIVATE Study Teams . Maraviroc for previously treated patients with R5 HIV-1 infection. N engl J Med. 2008; 359:1429-41.
  19. Fätkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman AI, Lampiris H, Hirschel B, tebas P, Raffi F, Trottier B, Bellos N, Saag M, Cooper DA, Westby M, Tawadrous M, Sullivan JF, Ridgway C, Dune MW, Felstead S, Mayer H, van der Ryst E, MOTIVATE 1 and MOTIVATE 2 Study Teams . Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med. 2008: 359:1442-55.
  20. Durante-Mangoni E, Bradley S, Selton-Suty C, Tripodi MF, Barsic B, Bouza E, Cabell CH, Ramos AI, Fowler V Jr, Hoen B, Konecny P, Moreno A, Murdoch D, Pappas P, Sexton DJ, Spelman D, Tattevin P, Miró JM, van der Meer JT, Utili R, International Collaboration on Endocarditis Prospective Cohort Study Group . Current features of infective endocarditis in elderly patients: results of the International Collaboration on Endocarditis Prospective Cohort Study. Arch Intern Med. 2008; 168:2095-103.
  21. Keynan Y, Rubinstein E . Endogenous Endophthalmitis Caused by hypermucoviscous Klebsiella pneumonia: An Emerging Disease in Southeast Asia and Beyond. Curr Infect Dis Rep. 2008; 10:343-5.
  22. Zhanel GG, Lam A, Schweizer F, Thomson K, Walkty A, Rubinstein E , Gin AS, Hoban DJ, Noreddin AM, Karlowsky JA. Ceftobiprole: A Review of a Broad-Spectrum and Anti-MRSA Cephalosporin. AM J Clin Dermatol. 2008; 9:245-254.
  23. TorresA, Garau J, Arvis P, Carlet J, Choudhri S, Kureishi A, Le Berre MA, Lode H, Winter J, Read RC, MOTIV (Moxifloxacin Treatment IV) Study Group . Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study - - a randomized clinical trial. Clin Infect Dis 2008; 46:1499-509.
  24. Rubinstein E. Staphylococcus aureus bacteraemia with known sources. Int J Antimicrob Agents. 2008 Aug 18.
  25. Regev-Yochay G, Bogaert D, Malley R, Hermans PW, Veenhoven RH, Sanders EA, Lipsitch M, Rubinstein E . Does pneumococcal conjugate vaccine influence Staphylococcus aureus carriage in children? Correspondence Clin Infect Dis 2008; 47 (15 Jul):289-91.
  26. Rubinstein E , Kollef MH, Nathwani D. Pneumonia caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2008 Mar 10; 46 (Suppl 5):S378-85.
  27. Caram LB, Linefsky JP, Read KM, Murdoch DR, Lalani T, Woods CW, Reller LB, Kani SS, Premru MM, Ryan S, Al-Hegelan M, Donnio PY, Orezzi C, Paival MG, Tribouilloy C, Watkin R, Harris O, Eisen DP, Corey GR, Cabell CH, Petti CA, International Collaboration on Endocarditis Investigator Group . Leptotrichia endocarditis: report of two cases from the International Collaboration on Endocarditis (ICE) database and review of previous cases. Eur J Clin Microbiol Infect Dis. 2008 Feb; 27(2):139-43
  28. Regev-Yochay G, Malley R, Rubinstein E , Raz M, Dagan R, Lipsitch M. In vitro bactericidal activity of Streptococcus pneumoniae and bactericidal susceptibility of Staphylococcus aureus strains isolated from co-colonized versus non-cocolinized children. J Clin Microbiol. 2008 Feb; 46(2): 747-9
  29. Baddley JW, Benjamin DK Jr, Patel M, Miró J, Atah E, Barsic B, Bouza E, Clara L, Elliott T, Kanafani Z, Klein J, Lerakis S, Levine D, Spelman D, Rubinstein E , Tornos P, Morris AJ, Pappas P, Fowler VG Jr, Chu VH, Cabell C, The International Collaboration on Endocarditis – Prospective Cohort Study Group (ICE-PCS). Candida infective endocarditis. Eur J Clin Microbiol Infect Dis. 2008 Feb 19
  30. Zhanel GG, Trapp S, Gin AS, DeCorby M, Lagacé-Wiens PR, Rubinstein E , Hoban DJ, Karlowsky JA. Dalbavancin and telavancin: novel lipoglycopeptides for the treatment of Gram-positive infections. Expert Rev Anti Infect Ther. 2008 Feb; 6(1):67-81.
  31. Mandell LA, Rubinstein E . HAP/VAP: Simpler may be better. Cam J Infect Dis Med Microbiol. 2008 Jan; 19(1):11
  32. Keynan Y, Rubinstein E . Fungal endocarditis. Curr Infect Dis Rep 2007; 1:25-32.
  33. Ariza J, Bosilkovski M. Cascio A, Colmenero JD, Corbel MJ, Falagas ME, Memish ZA, Roushan MR, Rubinstein E , Sipsas NV, Solera J, Young EJ, Pappas G, et al. Perspectives for the treatment of brucellosis in the 21 st century: the Ioannina recommendations. PLoS Med. 2007 Dec; 4(12):e317.
  34. Dickerman SA, Abrutyn E, Barsic B, Bouza E, Cecchi E, Moreno A, Doco-Lecompte, T, Eisen DP, Fortes CQ, Fowler VG Jr, Lerakis S, Miro JM, Pappas P, Peterson GE, Rubinstein E , Sexton DJ, Suter F, Tornos P, Verhagen Dw, Cabell CH, ICE Investigators. The relationship between the initiation of antimicrobial therapy and the incidence of stroke in infective endocarditis: an analysis from the ICE Prospective Cohort Study (ICE-PCS). Am Heart J. 2007; 154:1086-94.
  35. Höffken G, Barth J, Rubinstein E , Beckmann H, for the HAP study group. A Randomized Study of Sequential Intravenous/Oral Moxifloxacin in Comparison to Sequential Intravenous Caftriaxon/Oral Cefuroxime Axetil in Patients with Hospital-Acquired Pneumonia. Infection 2007 Nov 22.
  36. Keynan Y, Rubinstein E . Fungal Endocarditis: Combined Medical & Surgical Therapy Revisted. Antibiotics For Clinicians p425-29, Jul-Sep, 2007.
  37. Rubinstein E . Short antibiotic treatment courses or how short is short? Int J Antimicrob Agents. 2007 30S:S76-S79.
  38. Keynan Y, Rubinstein E . The changing face of Klebsiella pnuemoniae infections in the community. Int J Antimicrob Agents. 2007; 30:385-389.
  39. Keynan Y, Rubinstein E . Diabetes mellitus and pyogenic liver abscess: risk and prognosis. Clin Infect Dis. 2007 Sep 15; 45:801
  40. Keynan Y, Karlowsky JA, Walus T, Rubinstein E . Pyogenic liver abscess causd by hypermucoviscous Klebsiella pneumoniae. Scan J Infect Dis. 2007; 39:828-30.
  41. Gin A, Dilay L, Karlowsky JA, Walkty A, Rubinstein E , Zhanel GG. Piperacillin-tazobactam: a beta-lactam/beta-lactamase inhibitor combination. Expert Rev Anti Infect Ther. 2007; 5(3):365-83.
  42. Zhanel GG, Wiebe R, Dilay L, Thomson K, Rubinstein E , Hoban DJ, Noreddin AM, Karlowsky JA. Comparative Review of the Carbapenems. Drugs. 2007; 67:1027-1052.
  43. Shurek KN, Wiebe R, Karloswky JA, Rubinstein E , Hoban DJ, Zhanel GG. Faropenem: review of a new oral penem. Expert Rev Anti Infect Ther. 2007; 5:185-98.
  44. Kuint J, Barzilai A, Regev-Yochay G, Rubinstein E , Keller N, Maayan-Metzger A. Comparison of community-acquired methicillin-resistant Staphylococcus aureus bacteremia to other staphylococcal species in a neonatal intensive care unit. Eur J Pediatr. 2007; 166:319-325
CHAPTERS IN BOOKS
  1. E Rubinstein , I Levi & B Rubinovitch. Generalized Lymphadenopathy. Ed. Cohen, Powderly Opal et al. Infectious Diseases 3 rd Edition, Mosby 2009.
  2. Y Keynan and E Rubinstein . Solitary lymphadenitis. Ed. Cohen, Powderly Opal et al. Infectious Diseases 3 rd Edition, Mosby 2009.
  3. P. Lagace-Wiéns and E Rubinstein . Cardiac Aspergillosis. Ed. A Pasqualotto. Aspergillosis: From Diagnosis to Prevention, Springer 2009.
  4. E Rubinstein , M Koleff. Staphylococcal Pneumonia. Ed. Crossely K, Archer G, Fowler V, Jefferson K, The Staphylococci in Human Disease, 2 nd edition, Blackwell Publishing Ltd. 2009.